Stage III Ovarian Epithelial Cancer Completed Phase 2 Trials for Imatinib (DB00619)

IndicationStatusPhase
DBCOND0028510 (Stage III Ovarian Epithelial Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00036751Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal CancerTreatment